Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma

References

• Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993;342:1317–1322.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Committee to Advise the Public Health Service on Clinical Practice Guidelines [Internet]; Field M, Lohr K, editors. Clinical practice guidelines: directions for a new program. Washington (DC): National Academy Press; 1990. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25144032
   Google Scholar
• Cohen JB, Zain JM, Kahl BS. Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies. Am Soc Clin Oncol Educ Book. 2017;37:512–525.
   PubMedGoogle Scholar
• Dabaja BS, Advani R, Hodgson DC, et al. ACR Appropriateness Criteria® diffuse large b-cell lymphoma. Am J Clin Oncol. 2015;38:610–620.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Zelenetz AD, Gordon LI, et al. NCCN Guidelines Insights: Non-Hodgkin’s Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016;14:1067–1079.
   PubMed Web of Science ®Google Scholar
• Winkfield KM, Advani RH, Ballas LK, et al. ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology (Williston Park). 2016;30:1099–1103.
   PubMed Web of Science ®Google Scholar
• Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A Framework for Improvement. JAMA. 1999;282:1458–1465.
   PubMed Web of Science ®Google Scholar
• Guideline Summaries [Internet]. Natl. Guidel. Clear; 2016. Available from: https://www.guideline.gov/search?f_DocType=0&fLockTerm=Guideline Summaries
   Google Scholar
• Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ. 1997;157:408–416.
   PubMed Web of Science ®Google Scholar
• Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care. 2001;39:II46–II54.
   PubMed Web of Science ®Google Scholar
• Cervero RM, Gaines JK. The impact of CME on physician performance and patient health outcomes: an updated synthesis of systematic reviews. J Contin Educ Health Prof. 2015;35:131–138.
   PubMed Web of Science ®Google Scholar
• Bryan C, Boren SA. The use and effectiveness of electronic clinical decision support tools in the ambulatory/primary care setting: a systematic review of the literature. Inform Prim Care. 2008;16:79–91.
   PubMedGoogle Scholar
• Kawamoto K, Houlihan CA, Balas EA, et al. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ. 2005;330:765.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Han X, Jemal A, et al. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016;122:2356–2363.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150:200–208.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355–362.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–575.
   PubMed Web of Science ®Google Scholar
• Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–953.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–1260.
   PubMed Web of Science ®Google Scholar
• Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4:e15–e23.
   PubMed Web of Science ®Google Scholar
• Verhoef G, Robak T, Huang H, et al. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica. 2017;102:895–902.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013; 31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Koff JL, Flowers CR. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies. Oncology (Williston Park). 2013;27:8–12.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659–667.
   PubMed Web of Science ®Google Scholar
• Johnson SS, Castle PH, Van Marter D, et al. The effect of physician continuing medical education on patient-reported outcomes for identifying and optimally managing obstructive sleep apnea. J Clin Sleep Med. 2015;15:197–204.
   Google Scholar
• Toftegaard BS, Bro F, Falborg AZ, et al. Impact of continuing medical education in cancer diagnosis on GP knowledge, attitude and readiness to investigate - a before-after study. BMC Fam. Pract. 2016;17:95.
   PubMed Web of Science ®Google Scholar
• Casebeer L, Brown J, Roepke N, et al. Evidence-based choices of physicians: a comparative analysis of physicians participating in Internet CME and non-participants. BMC Med Educ. 2010;10:42.
   PubMed Web of Science ®Google Scholar
• Casebeer L, Engler S, Bennett N, et al. A controlled trial of the effectiveness of internet continuing medical education. BMC Med. 2008;6:37.
   PubMed Web of Science ®Google Scholar